Almirall Receives Positive CHMP Opinion for Dimethyl Fumarate for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis
(WorldNews Spain)

Dimethyl fumarate (DMF) is a fumaric acid ester indicated as an oral first-line treatment for adults with moderate-to-severe chronic plaque psoriasis Results from the randomised, double-blind, placebo-controlled Phase III trial (BRIDGE) showed the efficacy and safety of dimethyl fumarate (DMF) Dimethyl fumarate is due to be marketed in Europe from Q3 2017 Barcelona, 21st April 2017 `We are proud of the positive recommendation announced by the CHMP for dimethyl fumarate as this will provide European patients and healthcare professionals with a new therapeutic alternative in the systemic treatment of this chronic dermatological disease`, commented Eduardo Sanchiz, Almirall`s CEO. `This is a...